These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 30177965)

  • 1. Nanomedicine: Principles, Properties, and Regulatory Issues.
    Soares S; Sousa J; Pais A; Vitorino C
    Front Chem; 2018; 6():360. PubMed ID: 30177965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized Nanomedicine: A Revolution at the Nanoscale.
    Fornaguera C; García-Celma MJ
    J Pers Med; 2017 Oct; 7(4):. PubMed ID: 29023366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Where Is Nano Today and Where Is It Headed? A Review of Nanomedicine and the Dilemma of Nanotoxicology.
    Domingues C; Santos A; Alvarez-Lorenzo C; Concheiro A; Jarak I; Veiga F; Barbosa I; Dourado M; Figueiras A
    ACS Nano; 2022 Jul; 16(7):9994-10041. PubMed ID: 35729778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges.
    Musazzi UM; Franzè S; Condorelli F; Minghetti P; Caliceti P
    Adv Healthc Mater; 2023 Dec; 12(30):e2301956. PubMed ID: 37718353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicines accessible in the market for clinical interventions.
    Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
    J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Pharmaceutical Nanomedicines: From the Bench to the Market.
    Halwani AA
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines.
    Albalawi F; Hussein MZ; Fakurazi S; Masarudin MJ
    Int J Nanomedicine; 2021; 16():161-184. PubMed ID: 33447033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Issues affecting nanomedicines on the way from the bench to the market.
    Longo JPF; Mussi S; Azevedo RB; Muehlmann LA
    J Mater Chem B; 2020 Dec; 8(47):10681-10685. PubMed ID: 33155000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicines for Renal Management: From Imaging to Treatment.
    Jiang D; Rosenkrans ZT; Ni D; Lin J; Huang P; Cai W
    Acc Chem Res; 2020 Sep; 53(9):1869-1880. PubMed ID: 32786331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory safety evaluation of nanomedical products: key issues to refine.
    De Jong WH; Geertsma RE; Borchard G
    Drug Deliv Transl Res; 2022 Sep; 12(9):2042-2047. PubMed ID: 35908133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping of the available standards against the regulatory needs for nanomedicines.
    Halamoda-Kenzaoui B; Holzwarth U; Roebben G; Bogni A; Bremer-Hoffmann S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1531. PubMed ID: 29923692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicines: addressing the scientific and regulatory gap.
    Tinkle S; McNeil SE; Mühlebach S; Bawa R; Borchard G; Barenholz YC; Tamarkin L; Desai N
    Ann N Y Acad Sci; 2014 Apr; 1313():35-56. PubMed ID: 24673240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicines: The magic bullets reaching their target?
    Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
    Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale.
    das Neves J; Bahia MF; Amiji MM; Sarmento B
    Expert Opin Drug Deliv; 2011 Aug; 8(8):1085-104. PubMed ID: 21599564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicines and Nanosimilars: Looking for a New and Dynamic Regulatory "Astrolabe" Inspired System.
    Demetzos C; Kavatzikidou P; Pippa N; Stratakis E
    AAPS PharmSciTech; 2020 Jan; 21(2):65. PubMed ID: 31933006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulating nanomedicine - can the FDA handle it?
    Bawa R
    Curr Drug Deliv; 2011 May; 8(3):227-34. PubMed ID: 21291376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nanomedicines alliance: an industry perspective on nanomedicines.
    Malinoski FJ
    Nanomedicine; 2014 Nov; 10(8):1819-20. PubMed ID: 25038497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smart Nanosystems for Overcoming Multiple Biological Barriers in Cancer Nanomedicines Transport: Design Principles, Progress, and Challenges.
    Lin G; Zhou J; Cheng H; Liu G
    Small; 2023 Jul; 19(28):e2207973. PubMed ID: 36971279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality-by-Design Concepts to Improve Nanotechnology-Based Drug Development.
    Rawal M; Singh A; Amiji MM
    Pharm Res; 2019 Sep; 36(11):153. PubMed ID: 31482243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.